On Friday, Quest Diagnostics Inc(NYSE:DGX)’s shares declined -1.06% to $70.18.
Quest Diagnostics (DGX), the world’s leading provider of diagnostic information services, declared that its Board of Directors declared a quarterly cash dividend of $0.38 per share, payable on October 21, 2015 to shareholders of record of Quest Diagnostics common stock on October 6, 2015.
Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, in addition to related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry.
Forest City Enterprises, Inc. (NYSE:FCE.A)’s shares dropped -2.17% to $22.08.
Forest City Enterprises, Inc. (NYSE:FCEA ) declared that its Board of Directors has set the date of a special meeting of shareholders in connection with the company’s formerly declared plan to convert to a real estate investment trust (“REIT”). The meeting will be held on October 15, 2015, at 2:00 p.m., Eastern Time. Shareholders of record as of the close of business on August 31, 2015, will be entitled to receive notice of and to vote at the meeting.
Forest City Enterprises, Inc. acquires, owns, develops, and manages commercial and residential real estate and land in the United States. The company’s Commercial group acquires, owns, develops, and operates regional malls, specialty/urban retail centers, office and life science buildings, and mixed-use projects, in addition to operates Barclays Center, a sports and entertainment arena located in Brooklyn, New York. Its Residential group acquires, owns, develops, and operates residential rental properties, counting upscale and middle-market apartments and adaptive re-use developments, in addition to develops and manages military family housing.
At the end of Friday’s trade, Coty Inc (NYSE:COTY)‘s shares dipped -1.29% to $28.30.
Coty Inc. (COTY) declared that its Board of Directors has approved a $700 million share repurchase authorization of its Class A common stock. This authorization comprises any amounts remaining under the existing stock repurchase authorization.
Repurchases will be made from time to time at the Company’s discretion, based on ongoing assessments of the capital needs of the business, the market price of its common stock, and general market conditions. No time has been set for the completion of the repurchase program, and the program may be suspended or suspended at any time. The repurchase program authorizes the Company to purchase its common stock from time to time through open market purchases, negotiated transactions or other means, counting 10b5-1 trading plans in accordance with applicable securities laws and other restrictions.
Coty Inc., together with its auxiliaries, manufactures, markets, and distributes beauty products worldwide. The company operates through three segments: Fragrances, Color Cosmetics, and Skin & Body Care. The company offers fragrances under the Calvin Klein, Marc Jacobs, Davidoff, Chloé, Balenciaga, Beyoncé, Bottega Veneta, Guess?, Katy Perry, and Roberto Cavalli brand names. It also provides lip, eye, nail, and facial color products under the Bourjois, Rimmel, Sally Hansen, and OPI brands. In addition, the company offers shower gels, deodorants, skin care, and sun treatment products under the adidas, Lancaster, philosophy, and Playboy brand names.
Sanofi SA (ADR) (NYSE:SNY), ended its Friday’s trading session with -2.05% loss, and closed at $49.51.
Sanofi Pasteur, the vaccines division of Sanofi, declared that Vaccine published positive results from a new analysis of data from a large-scale, multi-center efficacy trial. In this new analysis, researchers observed significantly fewer serious cardio-respiratory events possibly related to influenza (“the flu”) in study participants 65 years of age and older who received a higher-dose split-virus inactivated influenza vaccine (IIV-HD) contrast to a standard-dose split-virus inactivated influenza vaccine (IIV-SD).
In the efficacy trial, a total of 31,989 adults 65 years of age and older were randomly assigned in a 1:1 ratio to receive either IIV-HD (Fluzone® High-Dose vaccine, Sanofi Pasteur, Swiftwater, PA) or IIV-SD (Fluzone vaccine, Sanofi Pasteur) and followed for six to eight months post-vaccination for the occurrence of influenza and serious events, counting events leading to death or hospitalization (or its prolongation), or events considered life-threatening or medically important, or resulting in disability. For the supplementary analysis stated in Vaccine, cardio-respiratory events were grouped into seven categories: pneumonia, asthma, chronic obstructive pulmonary disease (COPD) or bronchial events, influenza (laboratory-confirmed influenza diagnosed outside of normal study procedures), other respiratory events, coronary artery events, congestive heart failure, and cerebrovascular events.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
